Fisher & Paykel Healthcare Corporation Ltd (fph) Logo

Fisher & Paykel Healthcare Corporation Ltd (FPH)

___:___ · Healthcare
0.00
0.00
(0.00)
VOLUME
DIV YIELD
PE RATIO
1 YR RETURN
52 WEEK RANGE

FPH Chart

Snapshot

FPH's Principal Activity is the designer, manufacturer and marketer of medical device products and systems for use in respiratory care, acute care and the treatment of obstructive sleep apnea.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume
Volume (4w avg)
Turnover
Open
Day Range -
VWAP
Prev Close
Last Trade

Performance

1 Week
1 Month
2022 YTD
1 Year
vs Sector (1yr) -8.75%
vs ASX 200 (1yr) -14.51%

Size

Market Capitalisation
ASX Rank 31 of 2,399
Sector Rank 3 of 207

Key Fundamentals

Shares Issued
Sector Healthcare
Similar Companies RHC / RMD / SHL
EPS $0.841
DPS $0.3829
NTA per share $0.00

Broker Consensus

Breakdown 2 Buy · 5 Hold · 6 Sell
Recommendation Sell
Last Updated 06/01/22

Announcements

Date Heading Pages File Size Time

Corporate Overview

Fisher & Paykel Healthcare Corporation Limited (FPH) is a New Zealand-based company engaged in design, development, manufacture and marketing of products and systems for use in respiratory care, acute care, surgery and the treatment of obstructive sleep apnea (OSA) in home and hospital. FPH currently sells its products and systems in over 120 countries around the world.

Incorporation Details

Incorporated Following the separation of Fisher & Paykel Industries Limited into two companies: Fisher & Paykel Healthcare Corporation Limited (FPH) and Fisher & Paykel Appliances Holdings Limited (FPA), listed on ASX on 21 Novemeber 2001.

Corporate Details

Head Office East Tamaki New Zealand 2013
Website www.fphcare.com
Registry Link Market Services
Auditor PricewaterhouseCoopers
Date Listed 21 Nov 2001

Upcoming Calendar (Forecasted)

Date Event
26/05/2022 Report (Prelim)
24/11/2022 Report (Interim)

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
02/12/2021 $0.1784 0% $0.1784 Interim 15/12/2021
24/06/2021 $0.2046 0% $0.2046 Final 07/07/2021
03/12/2020 $0.151 0% $0.151 Interim 16/12/2020
06/07/2020 $0.1463 0% $0.1463 Final 17/07/2020
06/12/2019 $0.1148 0% $0.1148 Interim 19/12/2019
13/06/2019 $0.1287 0% $0.1287 Final 05/07/2019
07/12/2018 $0.0921 0% $0.0921 Interim 21/12/2018
21/06/2018 $0.1151 0% $0.1151 Final 06/07/2018
05/12/2017 $0.0803 0% $0.0803 Interim 20/12/2017
15/06/2017 $0.1074 0% $0.1074 Final 07/07/2017
06/12/2016 $0.0789 0% $0.0789 Interim 21/12/2016
16/06/2016 $0.0955 0% $0.0955 Final 08/07/2016
09/12/2015 $0.0629 0% $0.0629 Interim 23/12/2015
17/06/2015 $0.071 0% $0.071 Final 10/07/2015
03/12/2014 $0.0537 0% $0.0537 Interim 19/12/2014
18/06/2014 $0.065 0% $0.065 Final 04/07/2014
02/12/2013 $0.0491 0% $0.0491 Interim 19/12/2013
17/06/2013 $0.0586 0% $0.0586 Final 05/07/2013
27/11/2012 $0.0426 0% $0.0426 Interim 14/12/2012
18/06/2012 $0.055 0% $0.055 Final 06/07/2012
28/11/2011 $0.0413 0% $0.0413 Interim 16/12/2011
20/06/2011 $0.0534 0% $0.0534 Final 08/07/2011
29/11/2010 $0.0418 0% $0.0418 Interim 17/12/2010
21/06/2010 $0.0578 0% $0.0578 Final 09/07/2010
03/12/2009 $0.0429 0% $0.0429 Interim 18/12/2009
15/06/2009 $0.056 0% $0.056 Final 06/07/2009

See Upcoming Dividends for all ASX companies.

Key Data
DPS(TTM) $0.3829
Gross DPS(TTM) $0.3829
Dividend yield
Gross yield
Payout Ratio 43%
DRP Yes
DRP Features 3% Discount

Directors & Management

Directors & Management

Name Title Since Bio
Dr Lisa Margaret McIntyre Non-Executive Director Oct 2021

Dr Lisa Margaret McIntyre

Non-Executive Director

Dr McIntyre has knowledge in health and technology - with experience in strategy, finance, technology transformation and data analytics. Dr McIntyre is an experienced company director with a portfolio that spans the health care, insurance, technology and e-learning sectors. She is currently a non-executive director of Insurance and Care NSW (a government public financial corporation), HCF Group (a private health insurance company in Australia), The University of Sydney, Studiosity and Nanosonics, and chair of LEK Consulting's ANZ Advisory Board. Prior to her director roles, Dr McIntyre spent 20 years as a senior strategy partner with LEK Consulting. She helped develop the company's US biotechnology advisory practice from three clients in the emerging sector to become the largest biotechnology practice in the US, providing strategic, commercial and operational advice to local and multinational companies in North America, Asia and Australia. She will also serve as a member of the Quality, Safety and Regulatory Committee, effective 1 October 2021 of FPH.

Mr Neville Mitchell Non-Executive Director Nov 2018

Mr Neville Mitchell

Non-Executive Director

Mr Mitchell was Chief Financial Officer and Company Secretary of Cochlear Limited between 1995 and 2017. He is non-executive director of Sonic Healthcare, Osprey Medical and Q'Biotics Group, a member of the Australian Board of Taxation, and a director of the South East Sydney Local Health District Board. Previously, he served on the New South Wales Medical Devices Fund, was Chairman of the Group of 100, and Chairman, Standing Committee (Accounting and Auditing), for the Australian Securities and Investments Commission. He is a member of Quality, Safety and Regulatory Committee.

Ms Philippa (Pip) Mary Greenwood Non-Executive Director Jun 2017

Ms Philippa (Pip) Mary Greenwood

Non-Executive Director

Ms Greenwood is a director of Spark New Zealand Limited, Westpac New Zealand Limited and a2 Milk Company Limited, a current trustee of the Auckland Writers Festival and served as a member of the New Zealand Takeovers Panel from 2007 to 2011. She was a partner at Russell McVeagh between 2001 and 2019 and previously served as the firm's Board Chair. She has advised on market transactions. She is the chairman of People Committee.

Mr Lewis George Gradon Chief Executive Officer,Managing Director Apr 2016

Mr Lewis George Gradon

Chief Executive Officer,Managing Director

Mr Gradon during his 37-year tenure with Fisher & Paykel Healthcare he has held various engineering positions overseeing the development of our range of products as well the development of our manufacturing, quality, intellectual property, supply chain and clinical research functions.

Mr Scott Andrew St John Non-Executive Director,Non-Executive Chairman Oct 2015

Mr Scott Andrew St John

Non-Executive Director,Non-Executive Chairman

Mr Carter was managing director of Foodstuffs New Zealand Limited for ten years until his retirement in 2010. He is chairman of the board of TR Group and Datacom Group, a director of Vector Limited and ANZ Bank New Zealand Limited, and a trustee of the Maurice Carter Charitable Trust. He is a member of Quality, Safety & Regulatory, People and Risk Committee.

Ms Geraldine Celia McBride Non-Executive Director Aug 2013

Ms Geraldine Celia McBride

Non-Executive Director

Ms McBride has been in the technology industry for 30 years and has global experience. She has held senior executive roles at SAP AG and Dell Inc, and is a former President of SAP North America. She is a director of National Australia Bank and Sky Network Television Ltd, and the founder and CEO of MyWave.

Mr Donal Paul O'Dwyer Non-Executive Director Dec 2012

Mr Donal Paul O'Dwyer

Non-Executive Director

Mr O'Dwyer is a director of Cochlear Limited, Mesoblast Limited and nib Holdings Limited. From 1996 to 2003, he was with Cordis Cardiology, initially as its president (Europe) and from 2000 to 2003 as its worldwide president. He worked for 12 years with Baxter Healthcare, as a plant manager in Ireland & then president of the Cardiovascular Group, Europe, now Edwards Lifesciences. He is the chairman of Quality, Safety & Regulatory Committee and member of People Committee.

Mr Michael Grenfell Daniell Non-Executive Director Nov 2001

Mr Michael Grenfell Daniell

Non-Executive Director

Mr Daniell is a member of the Council of the University of Auckland, a director of Cochlear Limited, Tait Limited and the Medical Research Commercialisation Fund, and Chair of the Medical Technologies Centre of Research Excellence. He is a member of Risk Committee.

Mr Marcus James Driller Company Secretary,Vice President - Corporate N/A

Director Transactions

FPH directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
06/12/21 Lisa McIntyre Buy +4,400 $32.452 $142,790 As advised by the company
16/09/21 Lewis Gradon Sell +80,000 $31.215 ($2,497,192) As advised by the company
16/09/21 Lewis Gradon Buy +32,466 $30.54 $991,511 Conversion of securities
16/09/21 Lewis Gradon Exercise 32,466 $30.54 $991,511 Conversion of securities
16/09/21 Lewis Gradon Buy +53,038 $30.54 $1,619,780 Exercise of options
16/09/21 Lewis Gradon Exercise 100,313 $30.54 $3,063,559 Exercise of options
01/09/21 Lewis Gradon Issued 25,761 $31.57 $813,274 Issue of securities
01/09/21 Lewis Gradon Issued 73,633 $31.57 $2,324,593 Issue of options
04/03/21 Scott St John Buy +500 $28.05 $14,025 As advised by the company
27/11/20 Scott St John Buy +1,500 $32.47 $48,705 As advised by the company
10/09/20 Lewis Gradon Exercise 64,598 $30.85 $1,992,848 Conversion of securities
10/09/20 Lewis Gradon Issued 22,178 $30.85 $684,191 Issue of securities
10/09/20 Lewis Gradon Sell +135,000 $33.822 ($4,565,936) As advised by the company
10/09/20 Lewis Gradon Issued 64,598 $30.85 $1,992,848 Conversion of securities
08/09/20 Lewis Gradon Issued 73,529 $31.27 $2,299,251 Issue of securities
08/09/20 Lewis Gradon Cancelled 111,364 $31.27 $3,482,352 Cancellation of securities
08/09/20 Lewis Gradon Issued 69,931 $31.27 $2,186,742 Issue of options
02/07/20 Michael Daniell Cancelled 20,000 $32.40 $648,000 Cancellation of securities
02/07/20 Michael Daniell Issued 15,901 $35.281 $561,004 Issue of securities
02/07/20 Lewis Gradon Sell +136,000 $34.307 ($4,665,765) As advised by the company
02/07/20 Lewis Gradon Issued 86,147 $0.035 $3,039 Issue of securities
02/07/20 Lewis Gradon Cancelled 115,000 $32.40 $3,726,000 Cancellation of securities
01/07/20 Scott St John Buy +1,500 $34.887 $52,330 As advised by the company
01/07/20 Michael Daniell Sell +90,000 $34.269 ($3,084,209) As advised by the company
03/12/19 Michael Daniell Issued 13,458 $21.30 $286,655 Issue of securities
03/12/19 Michael Daniell Cancelled 20,000 $20.24 $404,800 Cancellation of securities
03/12/19 Scott St John Buy +1,000 $21.20 $21,200 As advised by the company
02/12/19 Michael Daniell Sell +11,000 $22.004 ($242,040) As advised by the company
11/09/19 Lewis Gradon Issued 43,848 $15.84 $694,552 Issue of securities
11/09/19 Lewis Gradon Issued 138,827 $15.84 $2,199,020 Issue of options
26/06/19 Scott St John Buy +1,500 $15.26 $22,890 As advised by the company
11/06/19 Scott St John Buy +1,543 $15.42 $23,793 As advised by the company
12/03/19 Michael Daniell Sell +20,000 $15.045 ($300,900) As advised by the company
12/03/19 Michael Daniell Issued 20,882 $14.83 $309,680 Issue of securities
12/03/19 Michael Daniell Cancelled 40,000 $14.26 $570,400 Cancellation of securities

Director Interests

The current holdings of FPH directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Lisa McIntyre 06/12/2021 N/A 4,400 N/A N/A
Lewis Gradon 16/09/2021 518,159 642,280 282,391 N/A
Philippa (Pip) Greenwood 31/03/2021 N/A 3,800 N/A N/A
Scott St John 31/03/2021 21,000 N/A N/A N/A
Geraldine McBride 31/03/2021 1,262 N/A N/A N/A
Donal O'Dwyer 31/03/2021 N/A 68,569 N/A N/A
Neville Mitchell 31/03/2021 7,200 N/A N/A N/A
Michael Daniell 31/03/2021 N/A 900,168 N/A N/A

Shareholder Info

Top 20 Shareholders

Data supplied by Morningstar and accurate on Apr 27, 2021.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
HSBC Nominees (New Zealand) Limited 84,735,040 14.70%
HSBC Nominees (New Zealand) Limited I 66,978,951 11.62%
Jpmorgan Chase Bank 58,909,933 10.22%
Citibank Nominees (Nz) Ltd 41,810,783 7.25%
HSBC Custody Nominees (Australia) Limited 39,770,963 6.90%
Jpmorgan Nominees Australia Pty Limited 21,751,016 3.77%
Citicorp Nominees Pty Limited 18,666,433 3.24%
Tea Custodians Limited 15,191,575 2.64%
New Zealand Superannuation Fund Nominees Limited 12,416,669 2.15%
National Nominees New Zealand Limited 11,789,542 2.05%
Accident Compensation Corporation 9,617,415 1.67%
BNP Paribas Nominees Nz Limited Bpss40 9,391,635 1.63%
Cogent Nominees Limited 8,845,907 1.53%
Custodial Services Limited 7,542,681 1.31%
BNP Paribas Noms Pty Ltd 6,724,163 1.17%
National Nominees Limited 6,379,451 1.11%
Premier Nominees Limited 6,339,895 1.10%
FNZ Custodians Limited 6,193,852 1.07%
Custodial Services Limited I 5,953,253 1.03%
Jbwere (Nz) Nominees Limited 4,596,927 0.80%

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 15,263 8,994 1,950 1,180 79 27,466

Substantial Shareholders

A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.

Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.

Name Last Notice Total Shares Shares Held (%)
The Vanguard Group Inc. 27/04/2021 30,145,141 5.23
BlackRock, Inc and related bodies corporate 27/04/2021 28,725,458 4.98
Mitsubishi UFJ Financial Group, Inc 22/09/2021 35,213,089 6.10

Shareholders Buying

12 month transaction history compiled from ASX announcements.

Date Name Bought Previous % New %
22-09-21 Mitsubishi UFJ Financial Group, Inc 6,095,588 5.05 6.10
27-05-21 Mitsubishi UFJ Financial Group, Inc 29,117,501 -- 5.05

Shareholders Selling

12 month transaction history compiled from ASX announcements.

No sell transactions reported by Substantial Shareholders in the past 12 months.

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
2020 $32.84 30 June
2019 $14.83 28 June
2018 $13.68 29 June
2017 $10.85 28 June
2016 $9.56 28 June
2015 $6.09 30 June
2014 $4.43 30 June
FPH Historical Price Data (CSV)
Up to 20 years of EOD share price history
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.